XENE实时信号 | 通过Getagraph.com最大化利润

出售 117367 min ago

@ $49.08

发出时间: 14 Feb 2024 @ 00:05

回报率: -10.85%

上一信号: Feb 13 - 04:25

上一信号: 购买

回报率: -0.13 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada...

Stats
今日成交量	234 306
平均成交量	371 641
市值	3.30B
EPS	$0 ( 2024-02-29 )
下一个收益日期	( $-0.690 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.03
ATR14	$0.0380 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Von Seggern Christopher	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Aulin Sherry	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Kenney Christopher John	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Empfield James R.	Buy	65 000	Stock Option (Right to Buy)
2024-03-11	Robin Sherrington	Buy	65 000	Stock Option (Right to Buy)

INSIDER POWER
59.36
Last 100 transactions
Buy: 2 181 840 \| Sell: 619 411

音量相关性

長: 0.37 (neutral)

短: 0.85 (strong)

Signal:(68.805) Same movement expected

Xenon Pharmaceuticals Inc 相关性

10 最正相关
PAIC	0.905
TNGX	0.844
NEPH	0.843
BOTJ	0.842
ZS	0.842
IMCR	0.834
RYTM	0.831
GENY	0.827
SVAC	0.827
ASUR	0.827

10 最负相关
RAVN	-0.9
NETE	-0.871
RMRM	-0.853
BOCH	-0.849
EPZM	-0.832
SHSP	-0.824
MMAC	-0.824
GNLN	-0.807
AMRB	-0.807
EMBCV	-0.805

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Xenon Pharmaceuticals Inc 相关性 - 货币/商品

0.03
( neutral )

-0.05
( neutral )

0.00
( neutral )

0.12
( neutral )

-0.08
( neutral )

Xenon Pharmaceuticals Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-3.54M (0.00 %)
EPS:	$-2.73

FY	2023
营收:	$0
毛利润:	$-3.54M (0.00 %)
EPS:	$-2.73

FY	2022
营收:	$9.43M
毛利润:	$-96.33M (-1 021.13 %)
EPS:	$-2.07

FY	2021
营收:	$18.44M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.